XML 48 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation and Compensation Plans
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation and Compensation Plans Stock-Based Compensation and Compensation Plans The Company adopted its 2007 Stock Incentive Plan (the "2007 Plan") for employees, non-employee directors and consultants for the purpose of advancing the interests of the Company's stockholders by enhancing its ability to attract, retain and motivate persons who are expected to make important contributions to the Company. The 2007 Plan provided for the granting of stock option awards, RSUs, and other stock-based and cash-based awards. Following the effectiveness of the 2013
Stock Incentive Plan described below in connection with the closing of the Company's initial public offering, the Company is no longer granting additional awards under the 2007 Plan.
In August 2013, the Company's board of directors adopted, and the Company's stockholders approved, the 2013 Stock Incentive Plan (the "2013 Plan"), which became effective immediately prior to the closing of the Company's initial public offering. In June 2015, the Company’s board of directors adopted a first amendment to the 2013 Plan. The 2013 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, RSUs, restricted stock awards and other stock-based awards. Upon the effectiveness of the 2013 Plan, the number of shares of the Company's common stock that were reserved for issuance under the 2013 Plan was the sum of (1) a number of shares (up to a maximum of approximately 3,359,641 shares) that is equal to the sum of 739,317 shares (the number of shares of the Company's common stock then available for issuance under the 2007 Plan), and such number of shares of the Company's common stock that are subject to outstanding awards under the 2007 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right, plus (2) an annual increase, to be added the first business day of each fiscal year, beginning with the fiscal year ending December 31, 2014 and continuing until, and including, the fiscal year ending December 31, 2023, equal to the lowest of 2,542,372 shares of the Company's common stock, 4% of the number of shares of the Company's common stock outstanding on the first day of the fiscal year and an amount determined by its board of directors. The Company's employees, officers, directors, consultants and advisors are eligible to receive awards under the 2013 Plan. However, incentive stock options may only be granted to employees of the Company.
Annual increases under the evergreen provisions of the 2013 Plan have resulted in the addition of an aggregate of approximately 18,166,000 additional shares to the 2013 Plan, including for 2023, an increase of approximately 2,542,000 shares. As of December 31, 2022, the Company had approximately 166,000 shares available for grant under the 2013 Plan.
In October 2019, the Company's board of directors adopted the 2019 Inducement Stock Incentive Plan (the “2019 Inducement Plan”) to reserve 1,000,000 shares of its common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. In March 2020, the Company's board of directors amended the 2019 Inducement Plan to reserve an additional 1,000,000 shares of its common stock for issuance under the plan and in February 2021, the Company's board of directors further amended the 2019 Inducement Plan to reserve an additional 600,000 shares of its common stock for issuance under the plan. In September 2021, December 2021 and May 2022, the Company's board of directors further amended the 2019 Inducement Plan to reserve an additional 1,000,000 shares of common stock for issuance under the plan during each of the instances. In February 2023, the Company's board of directors further amended the 2019 Inducement Plan to reserve an additional 2,000,000 shares of common stock for issuance under the plan. The terms and conditions of the 2019 Inducement Plan are substantially similar to those of the 2013 Plan. As of December 31, 2022, the Company had approximately 791,000 shares available for grant under the 2019 Inducement Plan.
In April 2016, the board of directors adopted the ESPP pursuant to which the Company may sell up to an aggregate of 1,000,000 shares of common stock. The ESPP was approved by the Company’s stockholders in June 2016. The ESPP allows eligible employees to purchase common stock at a price per share equal to 85% of the lower of the fair market value of the common stock at the beginning or end of each six month offering period during the term of the ESPP. The first offering period began in September 2016. In December 2022, the ESPP was amended to permit employees to enroll any of four times each year.
A summary of the stock option activity, weighted average exercise prices, options outstanding and exercisable as of December 31, 2022, 2021 and 2020 is as follows (in thousands except weighted average exercise price):
 Years ended December 31,
 202220212020
 Common
Stock
Options		Weighted
Average
Exercise
Price		Common
Stock
Options		Weighted
Average
Exercise
Price		Common
Stock
Options		Weighted
Average
Exercise
Price
Outstanding, December 31, 202110,861 $10.94 8,928 $9.22 6,780 $10.89 
Granted3,812 $19.48 3,204 $13.03 2,630 $6.10 
Exercised(2,066)$3.84 (646)$2.80 (109)$2.89 
Expired or forfeited(204)$14.08 (625)$8.87 (373)$19.49 
Outstanding, December 31, 202212,403 $14.70 10,861 $10.94 8,928 $9.22 
 Years ended December 31,
 202220212020
Options exercisable at December 31, 20225,457 5,584 4,462 
Weighted average grant date fair value (per share) of options granted during the period$13.57 $10.53 $4.83 

As of December 31, 2022, there were approximately 11,847,000 options outstanding, net of estimated forfeitures, that had vested or are expected to vest. The weighted-average exercise price of these options was $14.66 per option; the weighted-average remaining contractual life of these options was 7.5 years; and the aggregate intrinsic value of these options was approximately $106.2 million. A summary of the stock options outstanding and exercisable as of December 31, 2022 is as follows (in thousands except exercise prices and weighted average exercise price):
 December 31, 2022
 Options OutstandingOptions Exercisable
Range of Exercise PricesTotal
Options
Outstanding		Weighted
Average
Remaining
Life (Years)		Weighted
Average
Exercise
Price		Number
Exercisable		Weighted
Average
Exercise
Price
$1.20-$2.96
1,266 5.3$2.43 1,263 $2.43 
$2.97-$4.88
1,280 6.1$4.02 1,021 $4.08 
$4.89-$8.07
2,319 7.8$6.73 1,171 $6.58 
$8.08-$15.00
2,644 8.6$12.88 705 $12.67 
$15.01-$73.22
4,894 7.9$25.43 1,297 $38.68 
12,403 7.6$14.70 5,457 $13.57 
Aggregate Intrinsic Value$109,659   $66,270  
Cash proceeds from, and the aggregate intrinsic value of, stock options exercised during the years ended December 31, 2022, 2021 and 2020, respectively, were as follows:
 Years ended December 31,
 202220212020
Cash proceeds from options exercised$7,943 $1,808 $314 
Aggregate intrinsic value of options exercised$23,628 $4,997 $393 
In connection with stock option awards granted to employees, non-employees directors and certain other individuals, the Company recognized approximately $16.1 million, $6.5 million and $4.7 million in share-based compensation expense during the years ended December 31, 2022, 2021 and 2020, respectively, net of expected forfeitures. As of December 31, 2022, there were approximately $66.9 million of unrecognized compensation costs, net of estimated forfeitures, related to stock option awards grants, which are expected to be recognized over a remaining weighted average period of 3.2 years.
The following table presents a summary of the Company's outstanding RSU awards granted as of December 31, 2022 (in thousands except weighted average grant-date fair value)
Restricted
Stock
Units		Weighted Average
Grant-Date
Fair Value
Outstanding, December 31, 20212,246 $9.82 
Awarded1,565 $19.15 
Vested(739)$7.81 
Expired or forfeited(46)$10.96 
Outstanding, December 31, 20223,026 $15.12 

As of December 31, 2022, there were approximately 2,788,000 RSUs outstanding, net of estimated forfeitures, that are expected to vest. The weighted-average fair value of these RSUs was $15.12 per share; and the aggregate intrinsic value of these RSUs was approximately $59.7 million.

In connection with RSUs granted to employees, non-employees directors and certain other individuals, the Company recognized approximately $10.2 million, $4.6 million and $3.3 million in share-based compensation expense during the years ended December 31, 2022, 2021, and 2020, respectively, net of expected forfeitures. As of December 31, 2022, there was approximately $36.4 million of unrecognized compensation costs, net of estimated forfeitures, related to RSU grants, which are expected to be recognized over a remaining weighted average period of 3.3 years. The total fair value of the RSUs that vested during the year ended December 31, 2022, was $5.8 million.

In connection with the ESPP made available to employees, the Company recognized approximately $0.4 million and $0.2 million of share-based compensation expense during the years ended December 31, 2022, and December 31, 2021, respectively, net of expected forfeitures. As of December 31, 2022, there was $0.1 million of unrecognized compensation costs, net of estimated forfeitures, related to the ESPP, which are expected to be recognized over 0.2 years. There were 41,016 and 51,951 shares of common stock issued under the ESPP during the year ended December 31, 2022, and 2021, respectively. Cash proceeds from ESPP purchases were approximately $0.5 million and $0.3 million during the year ended December 31, 2022, and 2021, respectively. As of December 31, 2022, 712,394 shares were available for future purchases under the ESPP.